Gallic acid suppresses the migration and invasion of PC-3 human prostate cancer cells via inhibition of matrix metalloproteinase-2 and -9 signaling pathways

  • Authors:
    • Kuo-Ching Liu
    • An-Cheng Huang
    • Ping-Ping Wu
    • Hui-Yi Lin
    • Fu-Shin Chueh
    • Jai-Sing Yang
    • Chi-Cheng Lu
    • Jo-Hua Chiang
    • Menghsiao Meng
    • Jing-Gung Chung
  • View Affiliations

  • Published online on: April 15, 2011     https://doi.org/10.3892/or.2011.1264
  • Pages: 177-184
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Epidemiological studies have demonstrated that a natural diet or consumption of fruits or vegetables can decrease the risk of cancer development. Cancer cells can migrate to and invade other organs or tissues that cause more difficulty to treat them and this also results in the need for treatments targeting multiple cellular pathways. Gallic acid (GA) has been demonstrated to possess multiple biological activities including anticancer function. However, no report exist on GA inhibited invasion and migration of human prostate cancer cells. We investigated the effects of migration and invasion in GA-treated PC-3 human prostate cancer cells with a series of in vitro experiments. Boyden chamber transwell assay was used to examine the migration and invasion of PC-3 cells. Western blotting, real-time PCR and gelatin zymography were used for determining the protein levels, gene expression and enzyme activities of matrix metalloproteinase-2 (MMP-2) and -9 in vitro. Results indicated that GA inhibited the invasion and migration of PC-3 cells and these effects are dose-dependent. GA inhibited the protein levels of MMP-2 and -9, son of sevenless homolog 1 (SOS1), growth factor receptor-bound protein 2 (GRB2), protein kinase C (PKC) and nuclear factor-κ B (NF-κB) p65, c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase 1/2 (ERK1/2), p38, p-AKT (Thr308) and p-AKT (Ser473), but it promoted the levels of phosphatidylinositol 3-kinase (PI3K) and AKT in PC-3 cells. GA also reduced the enzyme activities of MMP-2 and -9 in the examined cells. Moreover, the down-regulation of focal adhesion kinase (FAK) and Ras homolog gene family, member A (Rho A) mRNA expression levels, and up-regulation of the tissue inhibitor of metalloproteinase-1 (TIMP1) gene levels occurred in GA-treated PC-3 cells after 24 h treatment. Based on these observations, we suggest that GA might modulate through blocking the p38, JNK, PKC and PI3K/AKT signaling pathways and reducing the NF-κB protein level, resulting in the inhibition of MMP-2 and -9 of PC-3 human prostate cancer cells.

Related Articles

Journal Cover

July 2011
Volume 26 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu K, Huang A, Wu P, Lin H, Chueh F, Yang J, Lu C, Chiang J, Meng M, Chung J, Chung J, et al: Gallic acid suppresses the migration and invasion of PC-3 human prostate cancer cells via inhibition of matrix metalloproteinase-2 and -9 signaling pathways. Oncol Rep 26: 177-184, 2011
APA
Liu, K., Huang, A., Wu, P., Lin, H., Chueh, F., Yang, J. ... Chung, J. (2011). Gallic acid suppresses the migration and invasion of PC-3 human prostate cancer cells via inhibition of matrix metalloproteinase-2 and -9 signaling pathways. Oncology Reports, 26, 177-184. https://doi.org/10.3892/or.2011.1264
MLA
Liu, K., Huang, A., Wu, P., Lin, H., Chueh, F., Yang, J., Lu, C., Chiang, J., Meng, M., Chung, J."Gallic acid suppresses the migration and invasion of PC-3 human prostate cancer cells via inhibition of matrix metalloproteinase-2 and -9 signaling pathways". Oncology Reports 26.1 (2011): 177-184.
Chicago
Liu, K., Huang, A., Wu, P., Lin, H., Chueh, F., Yang, J., Lu, C., Chiang, J., Meng, M., Chung, J."Gallic acid suppresses the migration and invasion of PC-3 human prostate cancer cells via inhibition of matrix metalloproteinase-2 and -9 signaling pathways". Oncology Reports 26, no. 1 (2011): 177-184. https://doi.org/10.3892/or.2011.1264